Clinuvel PharmaceuticalsASX:CUV +2.51%85 FCF Margin % is 33.51% as of Dec. 2025, which is 24% below its 10-year median of 44.27. GuruFocus rates ASX:CUV with a GF Score™ of 85/100 and a GF Value™ of A$17.70 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 95.72% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (ASX:CUV) has a FCF Margin % of 33.51% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 24% below median its historical median of 44.27. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #41 out of 959 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Clinuvel Pharmaceuticals' FCF Margin % too high?
Clinuvel Pharmaceuticals' current FCF Margin % of 33.51% is 24% below median its 10-year median of 44.27. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #41 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #41 out of 959 companies for FCF Margin %. This places Clinuvel Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current FCF Margin % is 33.51%, which is 24% below median its own 10-year median of 44.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.70, compared to a current price of A$10.20 — trading 42.4% below its estimated fair value. The current FCF Margin % is 33.51%, which is 24% below median its 10-year median of 44.27. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current FCF Margin % is 33.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.20 is trading 42.4% below its estimated GF Value™ of A$17.70.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
FCF Margin %: 33.51% (24% below median its 10-year median of 44.27)
GF Value™: A$17.70 vs. price of A$10.20 (42.4% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for ASX:CUV
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
